Why the Rhythm (ASX:RHY) share price is climbing today

The medical technology company's shares continue their positive run. Let's take a look.

| More on:
medical research laboratory assistant examines solutions in test tubes

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is rising following the company's latest addition to its ColoSTAT clinical trial.

In early morning trade, the medical device company's shares were up 3.57% to $1.015 before retreating to $1.00 at the time of writing, up 2%.

What did Rhythm announce?

In its statement, Rhythm advised Sonic Healthcare Limited (ASX: SHL) business, Sonic Clinical Services, has joined its ColoSTAT clinical trial.

Rhythm's ColoSTAT is an experimental test kit that is being trialled as a low-cost, easy-to-use blood test to detect colorectal cancer.

Sonic Clinical Services' Independent Practitioner Network (IPN) Medical Centres will bring a network of independent clinicians across NSW and Victoria.

IPN is recognised as Australia's largest network of medical clinics. Currently, the business has more than 2,000 doctors across 160 medical centres nationally, providing 10 million consultations per year.

The first patients from Sonic Clinical Services' IPN medical centres have already been recruited.

Rhythm CEO Glenn Gilbert said:

We are already working with Sonic Healthcare under an existing partnership for the storage and testing of ColoSTAT blood samples as part of the Study 7 clinical trial.

Expanding this partnership with an additional division, in Sonic Clinical Services' IPN, is a natural progression that will ultimately contribute to the success of the ColoSTAT clinical trial.

More on ColoSTAT and the Rhythm share price

Rhythm develops and commercialises Australian medical diagnostics technology for sale in domestic and international markets. The company's ColoSTAT is the first proposed product-in-development intended to accurately test and detect the early stages of colorectal cancer.

It's estimated around 850,000 people lose their life from colorectal cancer each year.

In the United States, Europe, and Australia, more than 130 million people aged between 50-74 years are unscreened for colorectal cancer. This represents an addressable market opportunity of more than $6.5 billion.

The Rhythm share price has accelerated by 1,300% in the past 12 months, reflecting positive investor sentiment. Additionally, the company's shares reached an all-time high of $1.675 in March, before some profit-taking swooped.

At today's prices, Rhythm has a market capitalisation of roughly $205 million, with approximately 202 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »